South Korean biopharmaceutical firm Samsung Biologics has signed an agreement to manufacture Moderna’s Covid vaccine at its local factory. Under the agreement, the Samsung Group’s biotech arm will provide contract manufacturing organization (CMO) services to the US pharmaceutical manufacturer for its mRNA vaccine.
This means that some Moderna vaccines will be produced in South Korea. According to a report by the Yonhap news agency, the two sides held a vaccine partnership program in South Korea-US Washington, DC on Saturday with the presence of President Moon Jae-in. Samsung Biologics CEO John Rheem was present along with his Moderna counterpart Stephen Bansell, as well as Stanley Erk, CEO of Novavax, another US vaccine production company.
According to Moon’s office, Cheong Wa De, “the deal is expected to contribute to a steady accelerated supply of the Moderna vaccine in South Korea.”
Moon promised his government full support for vaccine developers manufacturers, citing the country’s goal of emerging as a ‘global vaccine production center’. Moon reported that he had agreed to establish a comprehensive global vaccine partnership between allies during the last day of US President Joe Biden’s summit. The president named it the ‘Vaccine Alliance’ to help America combine its core technologies with South Korea’s drug production capacity. AstraZeneca, Novavax Sputnik V vaccines are already being manufactured in the country.
Moderna also signed a memorandum of understanding (MoU) with the Ministry of Health Welfare, Ministry of Trade, Industry, South Korea. Under the MoU, Moderna agreed to invest in the recruitment of manpower to the mRNA vaccine production facility in South Korea. The ministries plan to provide support for Moderna’s investment business activities. The National Institute of Health of South Korea also signed a memorandum of understanding with Moderna to strengthen cooperation on research in infectious diseases.
- Some Moderna Vaccines Will Be Produced In South Korea
- The deal is expected to contribute to the steady accelerated supply of the Moderna vaccine in South Korea